All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | Modern drug discovery involves the identification of screening hits, [[medicinal chemistry|medicinal chemistry]] and optimization of those hits to increase the [[Affinity (pharmacology)#Protein-ligand binding|affinity]], [[binding selectivity|selectivity]] (to reduce the potential of side effects), efficacy/[[potency (pharmacology)|potency]], [[Metabolism|metabolic]] stability (to increase the [[Biological half-life|half-life]]), and oral [[bioavailability|bioavailability]]. Once a compound that fulfills all of these requirements has been identified, it will begin the process of [[drug development|drug development]] prior to [[clinical trial|clinical trial]]s. One or more of these steps may, but not necessarily, involve [[computer-aided drug design|computer-aided drug design]]. |
| h Japanese (ja) | 現代の創薬では、[[Affinity (pharmacology)#Protein-ligand binding/ja|親和性]]、[[binding selectivity/ja|選択性]]（副作用の可能性を減らす）、有効性／[[potency (pharmacology)/ja|効力]]、[[Metabolism/ja|代謝]]安定性（[[Biological half-life/ja|半減期]]を長くする）、経口[[bioavailability/ja|バイオアベイラビリティ]]を高めるために、スクリーニングでヒットした[[medicinal chemistry/ja|化合物]]を特定し、薬化学的に最適化する。これらの要件をすべて満たす化合物が同定されると、[[clinical trial/ja|臨床試験]]に先立ち、[[drug development/ja|薬物開発]]のプロセスが開始される。これらのステップの1つ以上には、必ずしも[[computer-aided drug design/ja|コンピュータ支援薬物設計]]が含まれるとは限らない。 |